As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza and pandemic preparedness. With state-of-the-art production facilities and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. CSL Seqirus operates Australia’s only manufacturing facility for seasonal and pandemic influenza vaccines, and produces a range of unique medicines in the national interest including antivenoms and the only human vaccine for Q fever. The company also in-licenses a broad range of vaccines and specialty pharmaceutical products. As the world's only manufacturer of antivenoms specific to Australian fauna, CSL Seqirus is committed to reducing the burden of venomous bites and stings through awareness, education and community programs. The manufacture of antivenoms is supported through funding by the Australian Government Department of Health.